57 related articles for article (PubMed ID: 26695174)
1. Subcutaneous nodules secondary to exenatide once weekly: clinical and histological findings.
Donato S; Sargento D; Soares-de-Almeida L; Uva L
Acta Diabetol; 2016 Aug; 53(4):681-2. PubMed ID: 26695174
[No Abstract] [Full Text] [Related]
2. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
Traina AN; Lull ME; Hui AC; Zahorian TM; Lyons-Patterson J
Can J Diabetes; 2014 Aug; 38(4):269-72. PubMed ID: 24797495
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
[TBL] [Abstract][Full Text] [Related]
4. [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014; 143 Suppl 2():23-7. PubMed ID: 25326840
[TBL] [Abstract][Full Text] [Related]
5. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
Murphy CE
Ann Pharmacother; 2012 Jun; 46(6):812-21. PubMed ID: 22669803
[TBL] [Abstract][Full Text] [Related]
6. Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial).
Raskin P; Mohan A
Expert Opin Pharmacother; 2010 Sep; 11(13):2269-71. PubMed ID: 20536293
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Doggrell SA
Expert Opin Pharmacother; 2011 Sep; 12(13):2055-67. PubMed ID: 21534885
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
LaRue S; Malloy J
J Diabetes Sci Technol; 2015 Jul; 9(4):815-21. PubMed ID: 25759181
[TBL] [Abstract][Full Text] [Related]
9. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
[TBL] [Abstract][Full Text] [Related]
10. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
[TBL] [Abstract][Full Text] [Related]
11. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
[TBL] [Abstract][Full Text] [Related]
13. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Blonde L; Pencek R; MacConell L
Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
15. The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Roy D; Chadwick KD; Tatarkiewicz K; LaCerte C; Bergholm AM; Brodie T; Mangipudy RS; Parkes D; Graziano MJ; Reilly TP
Diabetes Obes Metab; 2014 Oct; 16(10):910-21. PubMed ID: 24666399
[TBL] [Abstract][Full Text] [Related]
16. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
Syed YY; McCormack PL
Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
19. [Development of multiple subcutaneous nodules in a patient with rheumatoid arthritis during methotrexate therapy].
Watanabe F; Yoshida T; Akizuki M; Mukai M
Ryumachi; 1993 Feb; 33(1):74-9. PubMed ID: 8493588
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
